Spectros Corporation Closes Technology Access Agreement With Caliper Life Sciences
PORTOLA VALLEY, Calif., June 4 /PRNewswire/ -- Spectros Corporation (Portola Valley, CA) signed an agreement with Caliper Life Sciences allowing Caliper limited access to certain Spectros optical imaging technologies for undisclosed terms. "We are pleased that Caliper Life Sciences has recognized the benefit and value of the broad and early optical biotechnology here at Spectros," notes David Benaron, CEO.
Spectros and its affiliates have over 70 patents in the U.S., Europe, and Japan assigned or in-licensed, forming one of the largest biophotonics intellectual property collections. Spectros core patents cover optical spectroscopy, fluorimetry, and imaging for use in blood analysis, contrast-targeted cancer surgery, lab-on-chip systems, and benchtop life sciences equipment, "Given the depth of our biophotonics patent portfolio, we anticipate significant top-line growth for our licensing program," commented David Benaron, CEO. Red Herring predicts that the total market for optical products in molecular detection, molecular imaging, and treatment guidance will grow to over $12 billion annually over the next five years.
ABOUT SPECTROS: Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. T-Stat(R), the Company's lead product, is FDA-approved and marketed in the U.S. and Europe for detection of ischemia, an insufficient blood flow to tissue. Spectros is co-developing an optical breast cancer screening device, currently in clinical trials, in conjunction with the University of California, the University of Pennsylvania, and others. Spectros out-licenses optical technology separate from these clinical product lines. Spectros is a venture-capital supported private concern.
(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future returns. Some applications described above are for investigational use only, and have not been reviewed and/or approved by the FDA.)
CONTACT: Elizabeth van Thillo of Spectros Corporation, +1-650-851-4040,
ext. 549, info@spectros.com
Web site: http://www.spectros.com/